Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year. ・Moderna was in focus after updated cancer vaccine data, while Novavax drew ...
Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of global product opportunity according to medical need and ...
Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza ...
Moderna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence ...
AptarGroup has recently declared a quarterly cash dividend of US$0.48 per share, payable on February 25, 2026, to ...
In 2025, Fundsmith Equity Fund began building a position in Zoetis, while the company reported third-quarter revenue growth ...
Per several third-party articles, Dr. Vinay Prasad — who heads the FDA’s Center for Biologics Evaluation and Research (CBER) — reportedly sent an internal memo to staffers on Friday acknowledging that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results